文献速递肝病消化道出血消化内镜

覆膜支架TIPS对比内镜套扎联合普萘洛尔预防合并门静脉血栓的肝硬化患者静脉曲张再出血:一项随机对照试验

Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
PubMed 文献 · Gut · 2017-09-28

本研究为随机对照试验,纳入近6周内发生静脉曲张出血且合并门静脉血栓的肝硬化患者,随机分为覆膜支架TIPS组(n=24)与内镜套扎联合普萘洛尔组(n=25)。中位随访30个月,TIPS组静脉曲张再出血显著少于联合治疗组(1年15% vs 45%,2年25% vs 50%;HR=0.28,95%CI 0.10至0.76,p=0.008),门静脉再通率显著更高(95% vs 70%;p=0.03),但生存率无显著差异(67% vs 84%;p=0.152)。

要点

  • 覆膜支架TIPS较内镜套扎联合普萘洛尔显著降低合并门静脉血栓肝硬化患者的静脉曲张再出血(HR=0.28)。
  • TIPS组门静脉再通率显著更高(95% vs 70%;p=0.03),再血栓率相对较低(5% vs 33%;p=0.06)。
  • 两组生存率(67% vs 84%;p=0.152)与显性肝性脑病发生率(25% vs 16%;p=0.440)无显著差异。

核心结论

  • 对于合并门静脉血栓且中度失代偿的肝硬化患者,覆膜支架TIPS在预防再出血方面比内镜套扎联合普萘洛尔更有效,门静脉血栓消退概率更高,且不增加显性肝性脑病和不良事件风险,但这一获益未转化为生存改善。

研究设计与样本

  • 随机对照试验,连续纳入近6周内发生静脉曲张出血且合并门静脉血栓的肝硬化患者(94%为Child-Pugh A或B级),随机分为TIPS组(n=24)与内镜套扎联合普萘洛尔组(n=25)。

主要发现

  • 中位随访30个月,TIPS组静脉曲张再出血1年为15% vs 联合治疗组45%,2年为25% vs 50%(HR=0.28,95%CI 0.10至0.76,p=0.008)。
  • TIPS组门静脉再通率为95% vs 联合治疗组70%(p=0.03)。
  • TIPS组再血栓率为5% vs 联合治疗组33%(p=0.06)。
  • 两组生存率为67% vs 84%(p=0.152),显性肝性脑病发生率为25% vs 16%(p=0.440),其他门静脉高压并发症及不良事件组间无统计学显著差异。

关键数值与推荐

  • 主要终点为静脉曲张再出血;次要终点包括生存、显性肝性脑病、门静脉再通与再血栓、其他门静脉高压并发症及不良事件。

临床怎么用

  • 作者认为,对于合并门静脉血栓且中度失代偿的肝硬化患者,覆膜支架TIPS在预防再出血方面比内镜套扎联合普萘洛尔更有效,且门静脉血栓消退概率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Limited data are available on the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT). This study aimed to compare transjugular intrahepatic portosystemic shunt (TIPS) with covered stents versus endoscopic band ligation (EBL) plus propranolol for the prevention of variceal rebleeding among patients with cirrhosis and PVT. DESIGN: Consecutive cirrhotic patients (94% Child-Pugh class A or B) with PVT who had variceal bleeding in the past 6 weeks were randomly assigned to TIPS group (n=24) or EBL plus propranolol group (EBL+drug, n=25), respectively. Primary endpoint was variceal rebleeding. Secondary endpoints included survival, overt hepatic encephalopathy (OHE), portal vein recanalisation and rethrombosis, other complications of portal hypertension and adverse events. RESULTS: During a median follow-up of 30 months in both groups, variceal rebleeding was significantly less frequent in the TIPS group (15% vs 45% at 1 year and 25% vs 50% at 2 years, respectively; HR=0.28, 95% CI 0.10 to 0.76, p=0.008), with a significantly higher portal vein recanalisation rate (95% vs 70%; p=0.03) and a relatively lower rethrombosis rate (5% vs 33%; p=0.06) compared with the EBL+drug group. There were no statistically significant differences in survival (67% vs 84%; p=0.152), OHE (25% vs 16%; p=0.440), other complications of portal hypertension and adverse events between groups. CONCLUSION: Covered TIPS placement in patients with PVT and moderately decompensated cirrhosis was more effective than EBL combined with propranolol for the prevention of rebleeding, with a higher probability of PVT resolution without increasing the risk of OHE and adverse effects, but this benefit did not translate into improved survival. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT01326949.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lv Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut. 2017. PMID: 28970291. doi:10.1136/gutjnl-2017-314634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。